Pharming Group (OTCMKTS:PHGUF) Shares Gap Up – Still a Buy?

Pharming Group NV (OTCMKTS:PHGUF)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $1.20, but opened at $1.30. Pharming Group shares last traded at $1.30, with a volume of 20,859 shares.

Pharming Group Stock Performance

The company has a market cap of $872.39 million, a P/E ratio of 65.03 and a beta of 0.47. The business’s 50 day simple moving average is $1.31 and its 200 day simple moving average is $1.56. The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.40.

Pharming Group (OTCMKTS:PHGUF) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.01) earnings per share for the quarter. The firm had revenue of $72.45 million during the quarter, compared to the consensus estimate of $92.06 million. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.